TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC grew its stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 8.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 973,466 shares of the company’s stock after acquiring an additional 72,967 shares during the quarter. Geode Capital Management LLC’s holdings in TScan Therapeutics were worth $4,849,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP purchased a new stake in shares of TScan Therapeutics in the second quarter valued at about $70,000. SG Americas Securities LLC purchased a new stake in shares of TScan Therapeutics in the 3rd quarter valued at approximately $78,000. The Manufacturers Life Insurance Company acquired a new stake in shares of TScan Therapeutics during the 2nd quarter worth approximately $90,000. XTX Topco Ltd purchased a new stake in shares of TScan Therapeutics during the 3rd quarter valued at approximately $112,000. Finally, MetLife Investment Management LLC lifted its holdings in TScan Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock valued at $116,000 after acquiring an additional 13,164 shares during the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Price Performance

TCRX stock opened at $3.07 on Friday. The business’s fifty day moving average price is $4.12 and its 200 day moving average price is $5.29. TScan Therapeutics, Inc. has a 12-month low of $2.60 and a 12-month high of $9.69. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $163.85 million, a PE ratio of -2.90 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. On average, sell-side analysts anticipate that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Wedbush restated an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Monday, December 23rd. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Wednesday, December 11th.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.